Polymorphism of estrogen metabolism genes and cataract

Medical Hypotheses

Volumn 63, Issue 3, 2004, Pages 494-497

  Lee, S M ^a,b   Tseng, L M ^a,b   Li, A F ^a,b   Liu, H C ^a,b   Liu, T Y ^a,b   Chi, C W ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; ESTRADIOL; ESTROGEN; TAMOXIFEN;

BREAST CARCINOMA; CANCER HORMONE THERAPY; CATARACT; CATARACTOGENESIS; DNA POLYMORPHISM; ESTRADIOL BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FOLLOW UP; HUMAN; HYPOTHESIS; MENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 3342889664     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.044     Document Type: Article

References (25)

1. McCartg C.A., Nanjan M.B., Taylor H.R. Attributable risk estimates for cataract to prioritize medical and public health action. Invest. Ophthalmol. Vis. Sci. 41:2000;3720-3725
2. Harding J.J. Cataract: biochemistry, epidemiology and pharmacology. 1991;Chapman and Hall, London. p. 83-124
3. Bron A.J., Sparrow J., Brown N.A., Harding J.J., Blackytny R. The lens in diabetes. Eye. 7:1993;260-275
4. Delaye M., Tardieu A. Short-range order of crystalline proteins accounts for eye lens transparency. Nature. 302:1983;415-417
5. Klein B.E., Klein R., Ritter L.L. Is there evidence of an estrogen effect on age related lens opacities? The Beaver Dam Eye Study. Arch. Ophthalmol. 112:1994;85-91
6. Freeman E.E., Munoz B., Schein O.D., West S.K. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation project. Arch. Ophthalmol. 119:2001;1687-1692
7. Klein B.E., Klein R., Lee K.E. Incidence of age-related cataract: the Beaver Dam Eye Study. Arch. Ophthalmol. 116:1998;219-225
8. Cumming R.G., Mitchell P. Hormone replacement therapy reproductive factors, and cataract. The Blue Mountains Eye Study. Am. J. Epidemiol. 145:1997;242-249
9. Benitez del Castillo J.M., del Rio T., Garcia-Sanchez J. Effect of estrogen use on lens transmittance in postmenopausal women. Ophthalmology. 104:1997;970-973
10. Ogueta S.B., Schwartz S.D., Yamashita C.K., Farber D.B. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest. Ophthalmol. Vis. Sci. 40:1999;1906-1911
11. Kobayashi K., Kobayashi H., Ueda M., Honda Y. Estrogen receptor expression in bovine and rat retinas. Invest. Ophthalmol. Vis. Sci. 39:1998;2105-2110
12. Gorai I., Tanaka K., Inada M., et al. Estrogen-metabolizing gene polymorphisms, but not estrogen receptor-alpha gene polymorphisms, are associated with the onset of menarche in healthy postmenopausal Japanese women. J. Clin. Endocrinol. Metab. 88:2003;799-803
13. Hiraku Y., Yamashita N., Nishiguchi M., Kawanishi S. Catechol estrogens induce oxidative DNA damage and estadiol enhances cell proliferation. Int. J. Cancer. 92:2001;333-337
14. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59:1999;4870-4875
15. Picado-Leonard J., Miller W.L. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA. 6:1987;439-448
16. Landi M.T., Bertazzi P.A., Shields P.G., et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 4:1994;242-246
17. Yager J.D., Liehr J.G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36:1996;203-232
18. Worda C., Sator M.O., Schneeberger C., Jantschev T., Ferlitsch K., Huber J.C. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum. Reprod. 18:2003;262-266
19. Harding J.J. Estrogens and cataract. Arch. Ophthalmol. 112:1994;1511
20. Gail M.H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. 91:1999;1829-1846
21. Paganini-Hill A., Clark L.J. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 60:2000;167-172
22. Parkkari M., Paakkala A.M., Salminen L., Holli K. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol. Scand. 81:2003;495-499
23. Zhang J.J., Jacob T.J., Valverde M.A., et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J. Clin. Invest. 94:1994;1690-1697
24. Wang PN, Liu HC, Liu TY, et al. Estrogen metabolizing gene COMT polymorphism synergistic apolipoprotein E 4 allele increase the risk of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2004 [submitted]
25. Dehal S.S., Kupfer D. Evidence that catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56:1996;1283-1290